ARTICLE | Product Development

Under duress, biotechs will have to make hard decisions for patients and themselves about which trials to run

The COVID-19 crisis will make companies adopt clinical practices they should have embraced long ago

March 21, 2020 12:50 AM UTC

While COVID-19’s risk to clinical trials was initially a function of geography, the fallout for companies is now less a matter of where the studies are being run, and more about which patient population is involved, what resources are available and when the trials are due to start and read out.

Containment measures in major biotech hubs are putting broad swaths of preclinical research on hold, but biotechs are striving to stick to their clinical timelines, both as a matter of responsibility to patients and corporate survival...